Considerations in the treatment of geriatric depression: Overview of pharmacotherapeutic and psychotherapeutic treatment interventions

Research in Gerontological Nursing
Carlos H Rojas-FernandezCheryl A Sadowski

Abstract

Geriatric (or late-life) depression is common in older adults, with an incidence that increases dramatically after age 70 to 85, as well as among those admitted to hospitals and those who reside in nursing homes. In this population, depression promotes disability and is associated with worsened outcomes of comorbid chronic medical diseases. Geriatric depression is often undetected or undertreated in primary care settings for various reasons, including the (incorrect) belief that depression is a normal part of aging. Current research suggests that while antidepressant agent use in older adults is improving in quality, room for improvement exists. Improving the pharmacotherapy of depression in older adults requires knowledge and understanding of many clinical factors. The purpose of this review is to discuss salient issues in geriatric depression, with a focus on pharmacotherapeutic and psychotherapeutic interventions.

References

Nov 1, 1992·The American Journal of Psychiatry·G A Hinrichsen
Jan 1, 1982·Journal of Psychiatric Research·J A YesavageV O Leirer
Nov 1, 1993·The American Journal of Psychiatry·G S AlexopoulosT Kakuma
Apr 1, 1997·The American Journal of Psychiatry·K R KrishnanD G Blazer
Oct 27, 1997·JAMA : the Journal of the American Medical Association·B D LebowitzP Parmelee
Apr 18, 1998·Journal of Affective Disorders·N MittmannN H Shear
Mar 4, 2000·The American Journal of Psychiatry·M M MamdaniR E Upshur
Jul 13, 2000·Clinical Therapeutics·C Rojas-FernandezR Tonks
Sep 23, 2000·JAMA : the Journal of the American Medical Association·J W WilliamsA Sengupta
Apr 24, 2001·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·M P LuberG S Alexopoulos
Apr 27, 2001·Age and Ageing·D N Anderson
Dec 12, 2001·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·B H MulsantC F Reynolds
Mar 6, 2002·Current Drug Metabolism·Alex Hemeryck, Frans M Belpaire
Aug 29, 2002·The Journal of Clinical Psychiatry·Raymond W LamSidney H Kennedy
Oct 4, 2002·Biological Psychiatry·George S AlexopoulosK Ranga R Krishnan
Dec 11, 2002·JAMA : the Journal of the American Medical Association·Jürgen UnützerUNKNOWN IMPACT Investigators. Improving Mood-Promoting Access to Collaborative Treatment
Jul 16, 2003·Archives of General Psychiatry·Dennis S CharneyUNKNOWN Depression and Bipolar Support Alliance
Aug 2, 2003·Journal of the American Geriatrics Society·George S Alexopoulos
Aug 2, 2003·Biological Psychiatry·Robert M Carney, Kenneth E Freedland
Nov 7, 2003·Mayo Clinic Proceedings·Maria I Lapid, Teresa A Rummans
Mar 5, 2004·JAMA : the Journal of the American Medical Association·Martha L BruceGeorge S Alexopoulos
Mar 2, 2005·Journal of Clinical Psychopharmacology·Philip S WangJerry Avorn
Mar 24, 2005·The New England Journal of Medicine·Edward W Boyer, Michael Shannon
Apr 1, 2005·The American Journal of Psychiatry·Dan G BlazerCarl F Pieper
Apr 1, 2005·The American Journal of Psychiatry·Wenhui WeiStephen Crystal
Jun 7, 2005·Lancet·George S Alexopoulos
Jul 16, 2005·International Journal of Geriatric Psychiatry·Henry C DriscollCharles F Reynolds
Jul 20, 2005·Biological Psychiatry·George S AlexopoulosBarry D Lebowitz
Jul 20, 2005·Journal of Clinical Psychopharmacology·David J Kupfer
Nov 8, 2005·General Hospital Psychiatry·Stuart LevineChristopher A Langston
Jan 24, 2006·BMJ : British Medical Journal·Enid M HunkelerJürgen Unützer
Jan 27, 2006·The Cochrane Database of Systematic Reviews·P MottramJ Strobl
Mar 17, 2006·The New England Journal of Medicine·Charles F ReynoldsDavid J Kupfer
Apr 25, 2006·Journal of Clinical Psychopharmacology·Benoit H MulsantCharles F Reynolds
May 6, 2006·International Journal of Geriatric Psychiatry·Noora Sjösten, Sirkka-Liisa Kivelä
Oct 14, 2006·Journal of the American Geriatrics Society·Jürgen UnützerUNKNOWN IMPACT Investigators
Dec 13, 2006·Biological Psychiatry·Gustavo C Román

❮ Previous
Next ❯

Citations

Dec 21, 2013·Research in Social & Administrative Pharmacy : RSAP·Linda Simoni-WastilaJudith A Lucas
Oct 1, 2011·International Journal of Geriatric Psychiatry·Ladislav VolicerJenny T Van der Steen
Aug 28, 2020·Journal of Psychopharmacology·Rafae WathraDaniel M Blumberger
Sep 11, 2018·Dementia and Geriatric Cognitive Disorders·Michele LauriolaAntonio Greco

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2021 Meta ULC. All rights reserved